Pneumocystis jirovecii pneumonia medical therapy

Revision as of 19:02, 7 February 2012 by WikiBot (talk | contribs)
Jump to navigation Jump to search

Pneumonia Main Page

Pneumocystis jirovecii pneumonia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Pneumocystis jirovecii pneumonia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Pneumocystis jirovecii pneumonia medical therapy On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Pneumocystis jirovecii pneumonia medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Pneumocystis jirovecii pneumonia medical therapy

CDC on Pneumocystis jirovecii pneumonia medical therapy

Pneumocystis jirovecii pneumonia medical therapy in the news

Blogs on Pneumocystis jirovecii pneumonia medical therapy

Pneumocystis jirovecii pneumonia

Risk calculators and risk factors for Pneumocystis jirovecii pneumonia medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Trimethoprim-sulfamethoxazole is the drug of choice. Recommended alternatives include pentamidine; trimethoprim plusdapsone; atovaquone; and primaquine plus clindamycin.

References

Template:WH Template:WS